Variability in drug response as a factor in drug design

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 1, 1999, Pages 33-41

  Smith, Dennis A ^a   Jones, Barry ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMLODIPINE; ATENOLOL; AZITHROMYCIN; BENZTHIAZIDE; BETA 2 ADRENERGIC RECEPTOR; BETAXOLOL; CLOZAPINE; CYTOCHROME P450; DANAZOL; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUCONAZOLE; GRISEOFULVIN; HALOFANTRINE; KETOCONAZOLE; MEPHENYTOIN; METOPROLOL; NADOLOL; NIFEDIPINE; NITROFURANTOIN; OMEPRAZOLE; PHENYTOIN; PIRENZEPINE; RANITIDINE; SALBUTAMOL; SALMETEROL; TELENZEPINE; WARFARIN;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SOLUBILITY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032900660     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Urquhart J: Role of patient compliance in clinical pharmacokinetics. Clin Pharmacokin (1994) 27:202-215.
2. This paper introduces the concept of forgiveness' as an important parameter when considering variability in drug response.
3. Badawy SIF, Ghorab MM, Adeyeye CM: Characterization and bioavallabllity of danazol-hydroxypropyl β-cyclodextrin coprecipitates. IntJPharm (1996) 128:45-54.
4. Hasegawa A, Kawamura R, Nakagawa H. Sugimoto I: Physical properties of solid dispersions of poorly watersoluble drugs with enteric coating agents. Chem Pharm Bull (1985) 33:3429-3435.
5. Humberstone AJ, Porter CJH, Charman WN: A physicochemical basis for the effect of food on the absolute oral bioavailability of Halofantrine. J Pharm Sci (1996)85:525-529.
6. Baxter JG, Brass C, Schentag JJ. Slaughter RL: Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sc/(1986) 75:443-447.
7. Moolenaar F, Tramp TFJ, Huizinga T: Biopharmaceutical aspects of the absorption of orally administered nitrofurantoin. Pharm Weekbl (1975) 111:1253-1264.
8. Varia SA, Schuller S, Sloan KB, Stella VJ: Phenytoin prodrugs III: Water-soluble prodrugs for oral and/or parenteral use. J Pharm Sei (1984) 73:1068-1073.
9. Arias MJ, Gines JM, Moyano JR, Rabasco AM: The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene. J Drug Target (1994) 2:45-51.
10. He YL, Murby S. Warhurst G, Gitford J, Walker D, Ayrton J, Eastmond R, Rowland M: Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sei (1998) 87:626-633.
11. Smith SE: Physiology of the gastrointestinal tract in relation to drug absorption. Int Pharm J (I987) 1:101-104.
12. Melander A, Stenberg P, Uedholm H, Schersten B, WaahlinBoll E: Food-induced reduction in bioavaiiability of atenolol. Eur J ClinPharmacol(1979) 16:327-330.
13. Smith, DA, Jones BC, Walker DK: Design of drugs involving the concepts of theories of drug metabolism and pharmacokinetics. Med Res Rev (1996) 16:243-266.
14. This paper covers, in some depth, many of the concepts referred to in this review.
15. Maclntyre F, Smith DA, Coates PE: Variability in human pharmacokinetics in volunteer studies and in the clinical situation. European conference on specificity and variability in drug metabolism, Besancon, France, May 10-12, 1995. Symposium proceedings.
16. Wallis RM, Alker D, Surges RA, Cross PE, Greengrass PM, Mclntyre P, Quinn P: UK-84,149: a novel gut-selective spasmolytic with calcium antagonist activity. Br J Pharmacol (I994) 112:574P.
17. Smith DA, Jones BC: Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol (1992) 44:2089-2098.
18. This paper is a pivotal reference in the understanding of cytocnrome P450 substrate specificities.
19. Smith DA, Able SM, Hyland R, Jones BC: Human cytochrome P450s: Selectivity and measurement in vivo. Xenobiotica (1998) in press.
20. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J din Pharmacol(1998) 45:525-538.
21. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Trier (1997) 73:67-74.
22. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshelsky L, Crismon ML, Salelad SR, Hirschavitz J, Wagner R: Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res (1990) 7:347-351.
23. Steward DJ, Haining RL, Henné KR, Davis G, Rushmore TH, Trager WF, Rettie AE: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 7:361-367.
24. Jerting M, Merle Y, Mentré F, Mallet A: Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol (1997) 44:447-453.
25. Eiermann B, Engel G, Johansson l, Zanger UM, Bertilsson L: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol (1997) 44:439-446.
26. Levy G: Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokin (1998) 34:323-333.
27. This paper emphasizes the reasons for variability in drug performance.
28. 2c. receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet (1998) 7:1507-1509.
29. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R: Association between genetic polymorphisms of the 2adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest (1997) 100:3184-3188.
30. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB: Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the ,-adrenergic receptor. J Biol Chem (1996) 271:24029-24035.
31. 2H] telenzepine to muscarinic acetylcholine receptors in calf forebrain. Eur J Pharmacol (1988) 145:87-90.
32. Braat MCP, Jonkers RE, van Boxtel CJ: Quantification of metoprolol beta2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamlc modeling. Pulm Pharmacol (1992) 5:31-38.